Evolent Announces Third Quarter 2026 Results

(NYSE:EVH) Evolent Health, Inc. announced financial results for the three months ended September 30, 2026. Revenue for the quarter was $725,367,000, compared to $479,533,000 for the same period in 2025. Net loss attributable to common shareholders was $23,566,000, versus $26,930,000 in the prior year quarter. Net loss margin was (3.2)% compared to (5.6)% in Q3 2025. Adjusted EBITDA was $34,257,000, down from $38,955,000, with an Adjusted EBITDA margin of 4.7% versus 8.1% last year. Average Lives on Platform/Cases for the Performance Suite were 7,195, up from 6,474, while Specialty Technology and Services Suite averaged 74,733, down from 78,050. Administrative Services averaged 1,163, compared to 1,222, and Cases were 11, down from 13. Average Unique Members were 39,804, compared to 40,781. Average PMPM Fees/Revenue per Case for the Performance Suite was $26.14, up from $14.77, while Specialty Technology and Services Suite was $0.32, down from $0.40. Administrative Services PMPM was $13.84, down from $15.77. Medical Expense Ratio was 93.0%, up from 85.0%. Evolent announced one renewal and two new revenue agreements in the quarter, bringing the year-to-date total to seven. The company renewed its largest Surgical Management customer contract for four years. Evolent expanded an existing client relationship to provide oncology services across several additional states, representing approximately 1 million Commercial lives, with a January 1, 2027 go-live, and added Member Navigation across all existing and new lives. Evolent also expanded its relationship with a national payer in Specialty Technology & Services for oncology across 11 additional states. Cost of revenue for the quarter was $636,946,000, and selling, general and administrative expenses were $73,116,000. Loss per share attributable to common shareholders was $(0.21), compared to $(0.24) in Q3 2025. Total cash and cash equivalents as of September 30, 2026, was $148,255,000. Adjusted cost of revenue was $635,107,000, and adjusted selling, general and administrative expenses were $56,003,000. Adjusted income attributable to common shareholders was $7,296,000, or $0.06 per share, compared to $5,630,000, or $0.05 per share, in Q3 2025. For the nine months ended September 30, 2026, revenue was $1,874,133,000, and for the same period in 2025, it was $1,407,510,000. For the full year 2026, Evolent reiterated its revenue guidance range of $2.6 billion to $2.7 billion and raised its Adjusted EBITDA guidance to $130.0 million to $135.0 million. The company expects to deploy $26 million to $28 million in cash for capitalized expenditures during 2026. Goodwill as of September 30, 2026, was $694,420,000, and intangible assets, net, were $539,172,000. Total assets as of September 30, 2026, were $1,962,156,000.

Evolent Announces First Quarter 2026 Results

Evolent Health, Inc. (NYSE: EVH) announced its financial results for the three months ended March 31, 2026, reporting revenue of $496,246,000 and a net loss attributable to common shareholders of $26,632,000. The company highlighted successful, on-time oncology launches at Highmark and Aetna, and announced two new revenue agreements, including an expansion expected to generate over $200 million of annual revenue. Evolent reiterated its full-year 2026 revenue guidance range of $2.4 billion to $2.6 billion and Adjusted EBITDA range of approximately $110 million to $140 million. The company expects to deploy approximately $25 million to $30 million in cash for capitalized software development during 2026.